CG
ELGX

Cutler Group’s Endologix Inc ELGX Stock Holding History

Cutler Group’s Portfolio ELGX Stock Details ELGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-210
Closed -$1K – 6497
2017
Q3 		$1K Sell
210
-120
-36% -$5.47K ﹤0.01% 5698
2017
Q2 		$2K Hold
330
– – ﹤0.01% 5708
2017
Q1 		$1K Buy
+330
New +$21.8K ﹤0.01% 6173

Other funds holding ELGX

ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Cutler Group's ELGX Position: Q4 2017 in Review

Cutler Group sold out of Endologix Inc (ELGX) in Q4 2017, closing a stake of 449 shares — an estimated $20K sold.

Cutler Group first reported a position in ELGX in Q4 2015 and held it in 7 quarters. The position peaked at $22K in Q2 2017. 103 funds tracked by Wall St. Rank hold ELGX as of Q4 2017.

  • Cutler Group reported no remaining Endologix Inc position as of Q4 2017 after selling out during the quarter.
  • Cutler Group sold 449 Endologix Inc shares in Q4 2017, an estimated $20K.
  • Cutler Group first reported a position in Endologix Inc in Q4 2015 and held it in 7 quarters.
  • Cutler Group's Endologix Inc position peaked at $22K in Q2 2017.
  • 103 funds tracked by Wall St. Rank held Endologix Inc as of Q4 2017.

Based on Cutler Group's 13F filing for Q4 2017, filed 17 Jan 2018.